keyword
MENU ▼
Read by QxMD icon Read
search

teriparatide

keyword
https://www.readbyqxmd.com/read/28110392/tarsal-navicular-stress-fractures
#1
REVIEW
Rachel J Shakked, Emily E Walters, Martin J O'Malley
PURPOSE OF REVIEW: Navicular stress fractures are common in athletes and management is debated. This article will review the evaluation and management of navicular stress fractures. RECENT FINDINGS: Various operative and non-operative adjunctive treatment modalities are reviewed including the relevance of vitamin D levels, use of shock wave therapy and bone marrow aspirate concentrate (BMAC), and administration of teriparatide. Surgical treatment may be associated with earlier return to sports...
January 21, 2017: Current Reviews in Musculoskeletal Medicine
https://www.readbyqxmd.com/read/28103867/efficacy-of-teriparatide-in-the-treatment-of-nontraumatic-osteonecrosis-of-the-femoral-head-a-retrospective-comparative-study-with-alendronate
#2
Ryuta Arai, Daisuke Takahashi, Masahiro Inoue, Tohru Irie, Tsuyoshi Asano, Takuya Konno, Mohamad Alaa Terkawi, Tomohiro Onodera, Eiji Kondo, Norimasa Iwasaki
BACKGROUND: Collapse of the femoral head associated with nontraumatic osteonecrosis (NOFH) is one of the most common causes of disability in young adult patients. Excessive bone resorption by osteoclast coincident with the suppression of osteogenesis are believed to be responsible for collapse progression. Alendronate that inhibits bone resorption by inducing osteoclast apoptosis has been traditionally used for treating NOFH; however, several reports documented serious complications by the use of this drug...
January 19, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28090276/overexpression-of-recombinant-human-teriparatide-rhpth-1-34-in-escherichia-coli-an-innovative-gene-fusion-approach
#3
Nahid Bakhtiari, Zahra Amini Bayat, Sepideh Sagharidouz, Mohsen Vaez
BACKGROUND: Parathyroid hormone is an 84-amino acid peptide secreted by the parathyroid glands. Its physiological role is maintenance of normal serum calcium level and bone remodeling. Biological activity of this hormone is related to N-terminal 1-34 amino acids. The recombinant form of hormone (1-34) has been approved for treatment of osteoporosis from 2002. In this study, a novel fusion partner has been developed for preparation of high yield recombinant 1-34 amino acids of hPTH. METHODS: Novel nucleotide cassette designed encoding a chimeric fusion protein comprising of a fusion partner consisting of a His-tag in N-terminal, 53 amino acids belong to Escherichia coli (E...
January 2017: Avicenna Journal of Medical Biotechnology
https://www.readbyqxmd.com/read/28087282/short-term-perioperative-teriparatide-therapy-for-the-prevention-of-medication-related-osteonecrosis-of-the-jaw-a-randomized-controlled-preclinical-study-in-rats
#4
Mohammad Zandi, Arash Dehghan, Amirhossein Mohammadi-Mofrad, Payam Amini, Farshid Vahdatinia
OBJECTIVE: Dentoalveolar procedures in patients receiving bisphosphonates and other antiresorptive agents are associated with an increased risk of medication-related osteonecrosis of the jaw (MRONJ). The aim of present study was to evaluate the effects of perioperative teriparatide (TPD) therapy in prevention of MRONJ. SUBJECTS AND METHODS: Two protocols of TPD therapy were studied. For protocol A, 25 TPD-treated (AT) and 25 control (AC) rats received 5 weekly injection of 0...
December 19, 2016: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/28084543/-pregnancy-and-lactation-associated-osteoporosis
#5
M Gehlen, A D Lazarescu, C Hinz, B Boncu, N Schmidt, M Pfeifer, M Schwarz-Eywill, W Pollähne, H W Minne
Pregnancy and lactation-associated osteoporosis (PLO) is a rare form of osteoporosis, which occurs in the last trimester or postpartum. So far 100 cases have been published. The leading symptoms are severe low back pain or less frequently hip pain. Many patients develop postpartum depression due to inability to care for the baby and vertebral fractures. The therapeutic decision has to be made individually but teriparatid and bisphosphonates seem to be the best option. We report the clinical course (16 years) of a 37-year-old patient with PLO, who suffered 6 vertebral fractures...
January 13, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28071822/responses-to-treatment-with-teriparatide-in-patients-with-atypical-femur-fractures-previously-treated-with-bisphosphonates
#6
Nelson B Watts, Deborah Aggers, Edward F McCarthy, Tina Savage, Stephanie Martinez, Rachel Patterson, Erin Carrithers, Paul D Miller
If over-suppression of bone turnover explained the association between bisphosphonate use and atypical subtrochanteric femur fractures (AFF), this could be reversed with anabolic treatment such as teriparatide. We conducted a prospective, open label study in patients previously treated with bisphosphonates who sustained AFF, examining the response to 24 months treatment with teriparatide on bone mineral density (BMD), trabecular bone score (TBS), bone turnover markers (BTM) and fracture healing as well as quantitative histomorphometry...
January 10, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28058444/frequency-of-discontinuation-of-injectable-osteoporosis-therapies-in-us-patients-over-2%C3%A2-years
#7
A Modi, S Sajjan, R Insinga, J Weaver, E M Lewiecki, S T Harris
: Little is known about treatment patterns with injectable osteoporosis therapies. At 12 months, the probability of discontinuation was 69.1% among patients using ibandronate, followed by teriparatide (67.1%), zoledronic acid (59.2%), and denosumab (48.8%). By 24 months, discontinuation was higher for each treatment. The majority of US patients discontinue injectable osteoporosis treatment by the end of the first year following initiation. INTRODUCTION: This study was designed to assess the frequency of treatment discontinuation over time among patients who initiate injectable osteoporosis therapies...
January 5, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28038880/efficacy-and-safety-of-teriparatide-in-bisphosphonate-pretreated-and-treatment-naive-patients-with-osteoporosis-at-high-risk-of-fracture-post-hoc-analysis-of-a-prospective-observational-study
#8
Fumito Yoshiki, Atsushi Nishikawa, Masanori Taketsuna, Kenta Kajimoto, Hiroyuki Enomoto
BACKGROUND: Teriparatide is the first anabolic agent shown to reduce the risk of fractures in patients with osteoporosis. In Japan, teriparatide is prescribed to treat patients at high risk of fracture. Given that bisphosphonates are commonly used prior to teriparatide as treatment for osteoporosis, information on the effectiveness and safety of teriparatide with or without previous bisphosphonate treatment is helpful for physicians in clinical practice. This study aims to report the effectiveness and safety of teriparatide in treatment-naive and bisphosphonate-pretreated patients in Japan as real-world evidence...
December 27, 2016: Journal of Orthopaedic Science: Official Journal of the Japanese Orthopaedic Association
https://www.readbyqxmd.com/read/28028555/hip-and-other-fragility-fracture-incidence-in-real-world-teriparatide-treated-patients-in-the-united-states
#9
R T Burge, D P Disch, S Gelwicks, X Zhang, J H Krege
: This study demonstrates real-world effectiveness of teriparatide in reducing the risk of hip and other fragility fractures. Fracture incidence significantly decreased as adherence and persistence increased for any clinical, vertebral, nonvertebral, and hip fractures among patients who were observed for 2 years after teriparatide initiation. INTRODUCTION: Examine the relationship of treatment adherence and persistence to teriparatide with hip and other fractures...
December 27, 2016: Osteoporosis International
https://www.readbyqxmd.com/read/28019683/effect-of-teriparatide-or-risedronate-in-elderly-patients-with-a-recent-pertrochanteric-hip-fracture-final-results-of-a-78-week-randomized-clinical-trial
#10
Jorge Malouf-Sierra, Umberto Tarantino, Pedro A García-Hernández, Costantino Corradini, Søren Overgaard, Jan J Stepan, Lars Borris, Eric Lespessailles, Frede Frihagen, Kyriakos Papavasiliou, Helmut Petto, Per Aspenberg, José Ramón Caeiro, Fernando Marin
We present final results of a study comparing teriparatide 20 µg QD with risedronate 35 mg QW started within 2 weeks after surgery for a pertrochanteric hip fracture. Patients with BMD T-score ≤-2.0 and 25OHD >9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug. Primary endpoint was change from baseline in lumbar spine (LS) BMD at 78 weeks. Secondary and exploratory endpoints were change in BMD at the proximal femur, function, hip pain (Charnley score and 100 mm Visual Analog Scale [VAS]), quality of life (short form-36), radiology outcomes, and safety...
December 26, 2016: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28002913/pregnancy-associated-osteoporosis-pao-with-multiple-vertebral-fragility-fractures-diagnosis-and-treatment-in-a-young-primigravid-woman
#11
E Pola, D Colangelo, L A Nasto, V Pambianco, G Autore, V M Formica, G Maccauro
PAO is an uncommon condition affecting pregnant women during last trimester or early post-delivery period; it is often asymptomatic or presents with pain related to some acute fragility fractures. The diagnosis is often delayed or missed, the etiology remains unknown and no guidelines about treatment have been published. We present one case of PAO in a 33-year-old primigravid woman presenting acute worsening back pain. Our patient was treated with a TLSO brace, oral 25 (OH)-vitamin D supplementation and Teriparatide for 6 months...
October 2016: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/27999854/epidemiology-and-postoperative-outcomes-of-atypical-femoral-fractures-in-older-adults-a-systematic-review
#12
K S F Khow, P Shibu, S C Y Yu, M J Chehade, R Visvanathan
OBJECTIVE: To review the literature on epidemiology and postoperative outcomes particularly surgical, functional and quality of life of atypical femoral fractures (AFFs) in the older population (aged ≥65 years) using the first and second American Society of Bone Mineral Research (ASBMR) Task Force consensus definition. METHODS: Electronic search for articles on AFFs and bisphosphonates published in English was performed. Eligible studies were reviewed systematically in relation to (a) the epidemiology of AFFs in older people and (b) postoperative outcomes of AFFs...
2017: Journal of Nutrition, Health & Aging
https://www.readbyqxmd.com/read/27997614/effectiveness-of-teriparatide-on-fracture-healing-a-systematic-review-and-meta-analysis
#13
Zhongju Shi, Hengxing Zhou, Bin Pan, Lu Lu, Jun Liu, Yi Kang, Xue Yao, Shiqing Feng
PURPOSE: Nowadays, the efficacy of teriparatide in treating osteoporosis was widely accepted, but the discussion about using teriparatide to enhance fracture healing hasn't come to an agreement. This meta-analysis was conducted to evaluate the effectiveness of teriparatide for fracture healing. METHODS: We searched PubMed, the Cochrane Library, and Embase in August 2016 for randomized controlled trials (RCTs) which concerned the treatment of teriparatide for fracture healing...
2016: PloS One
https://www.readbyqxmd.com/read/27988794/teriparatide-treatment-in-a-heart-transplant-patient-with-a-chronic-kidney-disease-and-a-low-turnover-bone-disease-a-case-report
#14
A Fahrleitner-Pammer, D Wagner, P Krisper, K Amrein, H Dimai
Low-turnover bone disease is a complication of chronic kidney disease and a long-term steroid therapy. Currently, the only bone anabolic treatment available is teriparatide (TPTD). So far, no data exist in heart transplant patients, and only one single case with histomorphometric analysis of a dialysis patient with a low-turnover bone disease has been published. The current report shows the effect of a 1-year TPTD therapy in a cardiac transplant patient with 10 vertebral and 3 peripheral fractures who had developed a chronic kidney failure while receiving triple immunosuppressive therapy...
December 17, 2016: Osteoporosis International
https://www.readbyqxmd.com/read/27973466/treatment-of-menopausal-symptoms-new-era-with-new-options-or-new-options-for-menopausal-symptoms-after-15-years-of-whi-study
#15
Santiago Palacios, Pluvio J Coronado
Menopausal symptoms include vasomotor symptoms (VMS), vulvar-vaginal atrophy, and loss of bone mass associated with an increased risk of fracture. Treatment of VMS consists of lifestyle changes, hormone treatment (estrogens with and without progestogens, tissue selective estrogens complex or conjugated estrogens and bazedoxifene [CE/BZA], progestogens, and tibolone), and nonhormonal treatments. Genitourinary symptoms due to vulvar-vaginal atrophy are treated with systemic and local hormones, moisturizer creams and gels, CE/BZA, and a selective estrogen receptor modulator (ospemifene)...
December 14, 2016: Minerva Ginecologica
https://www.readbyqxmd.com/read/27966106/retreatment-with-teriparatide-our-experience-in-three-patients-with-severe-secondary-osteoporosis
#16
D L Mana, M B Zanchetta, J R Zanchetta
Teriparatide is a drug for the treatment of osteoporosis which is licensed for use for up to 24 months. There is little experience with retreatment. The aim of this study was to evaluate, in three patients with severe secondary osteoporosis, the response to a second cycle of teriparatide regarding bone mineral density (BMD) and osteocalcin. Case 1 : A 62-year-old woman with multiple vertebral fractures has received corticoids for a long time. After starting teriparatide, her BMD and osteocalcin increased. She then received ibandronate for 3 years but her BMD declined...
December 14, 2016: Osteoporosis International
https://www.readbyqxmd.com/read/27957280/the-influence-of-teriparatide-in-induced-tooth-movement-a-systematic-review
#17
REVIEW
Bianca-Núbia Souza-Silva, José-Lucas-Sani-de Alcântara Rodrigues, Jefferson-Chaves Moreira, Felipe-de Souza Matos, Carla-Patrícia-Hernandez-Alves-Ribeiro Cesar, Carlos-Eduardo-Palanch Repeke, Luiz-Renato Paranhos
BACKGROUND: Teriparatide is a synthetic drug similar than PTH (parathyroid hormone), which is currently used as long-term treatment option for patients with bone chronic diseases, as osteoporosis; and this drug can interfere in a positive way in orthodontic movement. Objectives: The medical literature was assessed in the present systematic review in order to determine the level of scientific evidence supporting the influence of teriparatide in induced tooth movement. MATERIAL AND METHODS: The PRISMA Checklist was followed in this systematic review...
December 2016: Journal of Clinical and Experimental Dentistry
https://www.readbyqxmd.com/read/27956123/case-based-review-of-osteonecrosis-of-the-jaw-onj-and-application-of-the-international-recommendations-for-management-from-the-international-task-force-on-onj
#18
REVIEW
Aliya A Khan, Archie Morrison, David L Kendler, Rene Rizzoli, David A Hanley, Dieter Felsenberg, Laurie K McCauley, Felice O'Ryan, Ian R Reid, Salvatore L Ruggiero, Akira Taguchi, Sotirios Tetradis, Nelson B Watts, Maria Luisa Brandi, Edmund Peters, Teresa Guise, Richard Eastell, Angela M Cheung, Suzanne N Morin, Basel Masri, Cyrus Cooper, Sarah L Morgan, Barbara Obermayer-Pietsch, Bente L Langdahl, Rana Al Dabagh, K Shawn Davison, George K Sándor, Robert G Josse, Mohit Bhandari, Mohamed El Rabbany, Dominique D Pierroz, Riad Sulimani, Deborah P Saunders, Jacques P Brown, Juliet Compston
Osteonecrosis of the jaw (ONJ) has been associated with antiresorptive therapy in both oncology and osteoporosis patients. This debilitating condition is very rare and advances in diagnosis and management may now effectively reduce the risk of its development and offer valuable treatment options for affected patients. This paper provides a case-based review of ONJ and application of the International Task Force on ONJ (referred to as the "Task Force") recommendations for the diagnosis and management of ONJ...
December 9, 2016: Journal of Clinical Densitometry
https://www.readbyqxmd.com/read/27933339/efficacy-and-safety-of-osteoporosis-medications-in-a-rat-model-of-late-stage-chronic-kidney-disease-accompanied-by-secondary-hyperparathyroidism-and-hyperphosphatemia
#19
M Ota, M Takahata, T Shimizu, Y Kanehira, H Kimura-Suda, Y Kameda, H Hamano, S Hiratsuka, D Sato, N Iwasaki
: This study showed that bisphosphonate was safe and effective for the treatment of bone disorders in stage 4 chronic kidney disease (CKD) rats. Intermittent teriparatide therapy showed an anabolic action on bone even under secondary hyperparathyroidism conditions without having an adverse effect on mineral metabolism in late-stage CKD. INTRODUCTION: Patients with late-stage CKD are at high risk for fragility fractures. However, there are no consensus on the efficacy and safety of osteoporosis medications for patients with late-stage CKD...
December 8, 2016: Osteoporosis International
https://www.readbyqxmd.com/read/27925287/treatment-sequence-matters-anabolic-and-antiresorptive-therapy-for-osteoporosis
#20
Felicia Cosman, Jeri W Nieves, David Dempster
The majority of osteoporosis medications are antiresorptive agents, which reduce the rate of bone remodeling. Within this group are the bisphosphonates, which inhibit protein prenylation in the mature osteoclast, reducing osteoclast capacity to resorb bone(1) and denosumab, a monoclonal antibody to rank ligand that inhibits osteoclast formation, function and survival(2) . Although several new anabolic agents are in development(3-5) , teriparatide is currently the only available anabolic therapy for osteoporosis in the United States, with the addition of only PTH(1-84) in the EU [referred to as PTH)...
December 7, 2016: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
keyword
keyword
112
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"